May 08, 2026

Reduced-Dose Radiation Shows Durable Control

Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.

Conexiant

May 06, 2026

Symptom Scores May Signal Neuropathy Risk

Early recovery symptom patterns may help clinicians identify which oropharyngeal cancer survivors warrant closer neurologic surveillance.

Conexiant

May 05, 2026

PET/CT and MRI Model May Help Stratify Prostate Cancer Risk

Retrospective multicenter radiomics study showed moderate to high discrimination in two small external cohorts

Conexiant

May 01, 2026

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches

Conexiant

April 17, 2026

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Conexiant

April 16, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

Conexiant

April 13, 2026

MRI May Improve Prostate Cancer Monitoring

Volume tracking and longitudinal imaging may enhance assessment of progression during active surveillance.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

June 06, 2025

Lower-Dose Treatment Effective in Anal Cancer Trial, Study

In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.

Conexiant